Pfizer-BioNTech begin global study of lead COVID-19 vaccine candidate
Moderna Inc also launched an advanced stage trial with 30,000 participants on Monday, and Johnson & Johnson is starting clinical trials this week.
- Country:
- United States
German biotech BioNTech and U.S. drugmaker Pfizer Inc said on Monday they would begin a global study to evaluate their lead COVID-19 vaccine candidate. If the study is successful, the companies could submit for regulatory approval as early as October, putting them on track to supply up to 100 million doses by the end of 2020 and 1.3 billion by the end of 2021.
The study is expected to include about 120 sites globally and could include up to 30,000 participants. Moderna Inc also launched an advanced stage trial with 30,000 participants on Monday, and Johnson & Johnson is starting clinical trials this week.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- BioNTech
- Pfizer Inc
- German
- Johnson & Johnson
- Moderna Inc
- COVID-19
ALSO READ
ICC has no authority to probe Philippines, Marcos tells Germany's Scholz
Germany is only halfway through property crisis, says Commerzbank real estate boss
Euro zone bond yields edge up, Italian-German spread hits fresh 26-month low
Soccer-Nagelsmann names six newcomers in Germany squad for France, Dutch friendlies
German government needs tighter conflict-of-interest guidelines, activists say